As recently reported, multiple sclerosis patients in the U.S. (age 22+) can with a prescription now obtain the portable neuromodulation stimulator (PoNS) device, which could improve walking ability in individuals with mild to moderate disease activity.1
Once again, there’s more clinical evidence that dietary interventions can positively impact the course of many autoimmune diseases, including multiple sclerosis (MS).
In treating patients with any neurological disease, it’s important to look at each case on an individual basis – what is helpful for one person may not be valuable in another, based on any number of variables.
New study finds vitamin D deficiency linked to impaired cognitive function even in early stages of MS.
And why we should include it in our assessment protocols.
In considering how we can best gauge brain health or the progression of a known disorder, practitioners do have many tools we can employ to get a truly comprehensive perspective to determine the most appropriate therapy.